OA01.06 Randomised Phase 2 Study of Nivolumab (N) Versus Nivolumab and Ipilimumab (NI) Combination in EGFR Mutant NSCLC
- Resource Type
- Source
- Journal of Thoracic Oncology. 16:S102-S103
- Subject
Pulmonary and Respiratory Medicine Oncology medicine.medical_specialty business.industry Internal medicine Mutant medicine Phases of clinical research Ipilimumab Nivolumab business medicine.drug - Language
- ISSN
- 1556-0864